According to South China Morning Post, AI drug design startup METiS TechBio raised HK$2.11 billion (US$269.5 million) in its Hong Kong IPO on May 13, with shares jumping on debut amid strong demand for AI-related stocks.
The company sold 201.23 million shares at HK$10.50 (US$1.3) each. Eighteen cornerstone investors, including BlackRock, UBS Asset Management Singapore, and Mirae Asset Securities, subscribed a combined US$148 million with a six-month lock-up agreement. METiS became the third AI drug developer to list in Hong Kong after XtalPi (June 2024) and Insilico Medicine (December 2025).
Related News
Anthropic talks $30 billion funding round, valuation could break $900B—challenging AI market-cap peak
Cerebras IPO Drives Supply Chain Gains: Vicor’s Power Narrative and AI Power IP Licensing Theme
OpenAI employees sell $6.6 billion worth of shares, with an average profit of $11 million per person